Welcome to our dedicated page for Entheon Biomedic news (Ticker: ENTBF), a resource for investors and traders seeking the latest updates and insights on Entheon Biomedic stock.
Entheon Biomedical Corp. (ENTBF) generates news primarily through its activities as a biotechnology research and development company interested in treating addiction and substance use disorders, as well as through significant corporate and transactional developments. Company disclosures describe Entheon’s focus within the healthcare and biotechnology sector and highlight its interest in mental health–related areas.
Recent news has centered on proposed corporate transactions and strategic directions. Entheon announced a binding Letter of Intent with Nutravisor Inc., under which Entheon would acquire all of the issued and outstanding common shares of Nutravisor. The company stated that, if completed, this proposed transaction would constitute a fundamental change under Canadian Securities Exchange Policy 8, result in a change of control, and lead to the combined entity continuing the business of Nutravisor as the Resulting Issuer, with an expected name change subject to approval. Earlier, Entheon also announced a binding letter of intent to acquire Mentis AI, a private research and development company focused on AI technologies for mental health and loneliness, and later reported that Mentis AI terminated that LOI.
Other news items include board changes, such as the appointment of a new director and the resignation of another, as well as the issuance of incentive stock options to certain directors under the company’s incentive stock option plan. These updates provide insight into Entheon’s governance, capital structure, and strategic considerations.
Investors and observers using this news page can review these announcements to understand how Entheon presents its biotechnology R&D focus, its interest in AI and mental health–related tools, and the potential impact of proposed fundamental transactions on the company’s future direction, subject to the stated conditions and regulatory processes.
Entheon (OTCQB: ENTBF) entered a definitive business combination agreement with Nutravisor dated January 19, 2026, to effect a three-cornered amalgamation and reverse takeover, after which Entheon will adopt Nutravisor’s business and change its name to STRYK Brands Inc.
Key terms: Nutravisor valued at $40,000,000; expected Nutravisor financings of $4.0M–$10.0M; Entheon consolidation ~6.93:1; issuance of ~53,333,333 post-consolidation shares to Nutravisor shareholders; exchange ratio 4.2395; voluntary lock-up releasing 25% every six months; finder’s fee $500,000. Closing remains subject to approvals and conditions.
Entheon (OTCQB: ENTBF) entered a binding Letter of Intent dated December 18, 2025 to acquire Nutravisor by share exchange, creating a Resulting Issuer led by Nutravisor management.
Terms include issuance of 53,333,333 Entheon shares at $0.75 each (approx. $40,000,000 post-consolidation), a required ~6.93:1 share consolidation, a $500,000 finder’s fee, a potential concurrent private placement up to $5,000,000, and a mutual break fee of $40,000. Closing is targeted by March 30, 2026, subject to due diligence, CSE approvals, listing, and other customary conditions; trading in Entheon shares was halted December 22, 2025.
Entheon Biomedical Corp (CSE: ENBI) (OTCQB: ENTBF) has announced a change in its Board of Directors. Harrison Newlands has been appointed to the board effective April 3, 2025, while Andrew Hegle has resigned.
Newlands brings nearly a decade of experience in start-ups and capital markets. His notable achievements include co-founding Fire & Flower, a Canadian retail cannabis company, where he served as Director of Business Development. He also co-founded Hoshi International, a medicinal cannabis producer in Portugal, and Hypercharge Networks, Canada's first publicly traded EV charging company.
His career began as a Research Associate at MacNicol and Associates on Bay Street. He has also served as a strategic advisor for Taiga Motors, was formerly a partner at Rockbank Capital, and currently serves as a managing partner at North King Capital, where he advises public and private companies.
Entheon Biomedical Corp (OTCQB: ENTBF) has announced the issuance of stock options to company directors. The granted options allow for the purchase of up to 40,000 common shares at an exercise price of $0.145 per share. These options will remain exercisable for a two-year period from the grant date. The options are governed under the company's incentive stock option plan, which was previously approved by shareholders at the annual general meeting on December 16, 2024.
Entheon Biomedical Corp (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU) has announced that Mentis AI (1000141080 Ontario ) has terminated the letter of intent (LOI) dated January 23, 2025. The LOI had outlined the terms for Entheon's proposed acquisition of all issued and outstanding common shares of Mentis AI. This termination follows the company's previous news release dated January 24, 2025.
Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) has announced a binding letter of intent to acquire Mentis AI, a private R&D company focused on AI technologies for mental health and loneliness solutions. The acquisition will provide Entheon with AI companions and coaching tools to enhance their existing HaluGen's Psychedelics and Lobo's Cannabis Genetic Test Kit services.
The transaction will be structured as a share exchange, with Mentis AI shareholders receiving 12.84296 Entheon shares for each Mentis AI share, totaling approximately 11 million Entheon shares. Post-transaction, Mentis AI shareholders will own about 44.25% of Entheon's outstanding shares. The deal must be completed by February 28, 2025, subject to due diligence, definitive agreement execution, and regulatory approvals.